

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Endocrine/metabolic disease</b>				
Diabetes	Toll-like receptor 9 (TLR9); IL-21	<i>In vitro</i> and mouse studies suggest adoptive transfer of TLR9-stimulated pro-B cells could help prevent type 1 diabetes. In nonobese diabetic (NOD) mice, adoptive transfer of bone marrow cells pretreated with a TLR9 agonist delayed disease onset and decreased pancreatic and plasma levels of IL-21 compared with adoptive transfer of cells pretreated with an inactive control oligonucleotide. Ongoing work includes testing adoptive transfer of TLR9-activated pro-B cells in mouse models for other autoimmune diseases.	Unpatented; unlicensed	Montandon, R. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online May 28, 2013; doi:10.1073/pnas.1222446110 <b>Contact:</b> Flora Zavala, University Paris Descartes, Paris, France e-mail: <a href="mailto:flora.zavala@parisdescartes.fr">flora.zavala@parisdescartes.fr</a>
		<b>SciBX 6(25); doi:10.1038/scibx.2013.626</b> <b>Published online June 27, 2013</b>		